To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.
The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].
The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.
Click on each trial for more detail of findings and quality.
Interventions for weight loss in people with chronic kidney disease who are overweight or obese.
Conley, M. M., et al. Cochrane Database of Systematic Reviews 2021; 3(3): CD013119.
The effect of cholecalciferol supplementation on allograft function in incident kidney transplant recipients: A randomized controlled study.
Doi, Y., et al. American Journal of Transplantation 2021 [record in progress].
Remnant cholesterol is prospectively associated with CVD events and all-cause mortality in kidney transplant recipients: the FAVORIT study.
Horace, R. W., et al. Nephrology Dialysis Transplantation 2021 [record in progress].
Personalized physical rehabilitation program and employment in kidney transplant recipients: A randomized trial.
Kastelz, A., et al. Transplant International 2021 [record in progress].
The ViKTORIES trial: a randomised, double-blind, placebo-controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients.
Lees, J. S., et al. American Journal of Transplantation 2021 [record in progress].
Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study.
Verhoeven, J., et al. Clin Epigenetics 2021; 13(1): 32.
Phase 3 trial Design of the Hepatocyte Growth Factor Mimetic ANG-3777 in Renal Transplant Recipients With Delayed Graft Function.
Vincenti, F., et al. KI Reports 2021; 6(2): 296-303.
Application of machine learning models for predicting acute kidney injury following donation after cardiac death liver transplantation.
He, Z. L., et al. Hepatobiliary & Pancreatic Diseases International 2021 [record in progress].
Unexpected CMV replication kinetics in CMV- donor seropositive recipient seronegative liver transplant recipients receiving preemptive antiviral therapy.
Singh, N., et al. Journal of Infectious Diseases 2021 [record in progress].
Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients.
Nair, N., et al. World Journal of Transplantation 2021; 11(3): 54-69.